IN RESPONSE, PLEASE REFER TO: M140509

June 5, 2014

MEMORANDUM TO: Mark A. Satorius

Executive Director for Operations

FROM: Annette Vietti-Cook, Secretary /RA/

SUBJECT: STAFF REQUIREMENTS – MEETING WITH THE ADVISORY

COMMITTEE ON THE MEDICAL USES OF ISOTOPES, 9:00 A.M., FRIDAY, MAY 9, 2014, COMMISSIONERS' CONFERENCE ROOM, ONE WHITE FLINT NORTH,

ROCKVILLE, MARYLAND (OPEN TO PUBLIC ATTENDANCE)

The Commission was briefed on a variety of medical issues by representatives from the Advisory Committee on the Medical Uses of Isotopes (ACMUI). The topics discussed included an Overview of ACMUI Activities; ACMUI's Position on Patient Release; Reliability of Radiation Safety Instructions for Patients Released Following Iodine-131 Therapy; ACMUI's Views on Revisions to the NRC Medical Use Policy Statement; the Food and Drug Administration's Radiation Regulatory Responsibilities; and General Views on the Regulation of Medical Uses of Byproduct Material – Part 35.

The staff should provide information to the Commission on the international practices of patient release following iodine-131 therapy, especially focusing on countries with advanced medical systems.

Consistent with Open Door Policies, ACMUI members should feel free to engage the Commissioners directly to discuss matters of interest and to share their expertise and experience.

We note that the discussion with the ACMUI representatives raised the question of whether the Agency might benefit from additional access to medical expertise. We also note that the Agency once maintained a "Visiting Fellows" program that sponsored medical experts to work with staff on a limited-term basis. Staff should provide a CA briefing to discuss its experience with this program and indicate whether it might provide support in the future.

cc: Chairman Macfarlane
Commissioner Svinicki
Commissioner Apostolakis
Commissioner Magwood
Commissioner Ostendorff

OGC CFO OCA OIP OIG

Office Directors, Regions, ACRS, ASLBP (via E-Mail)

PDR

OPA